Humanwell Healthcare (600079) H1 2026 earnings summary

Executive summary

• Achieved revenue of RMB 12.06 billion for H1 2026, flat year-over-year; net profit attributable to shareholders rose 15.15% to RMB 1.33 billion; adjusted net profit up 14.02% year-over-year.

• Maintained leading positions in anesthesia, steroid hormones, and ethnic medicines; continued international expansion with over 80 products exported to 70+ countries.

• Focused on innovation, with significant R&D investment and multiple clinical-stage projects; enhanced operational efficiency and risk management.

Financial highlights

• Operating income: RMB 12.06 billion, down 0.03% year-over-year.

• Net profit attributable to shareholders: RMB 1.33 billion, up 15.15% year-over-year.

• Adjusted net profit: RMB 1.29 billion, up 14.02% year-over-year.

• Basic and diluted EPS: RMB 0.81, up 14.08% year-over-year.

• Operating cash flow: RMB 1.00 billion, up 16.78% year-over-year.

• Gross margin improved due to cost control and product mix optimization.

Outlook and guidance

• Will continue to focus on core pharmaceutical segments and internationalization.

• Plans to accelerate R&D, especially in innovative and high-value drugs.

• Expects ongoing policy, regulatory, and market challenges but aims for steady growth through operational excellence and risk mitigation.